Loading stock data…
BeOne Medicines Ltd. (ONC)
$289.99+10.10 (+3.61%)
Market ClosedLast close Jun 29
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BeOne Medicines AG in the Healthcare sector is trading at $289.99 with a market capitalization of $30.1B. Wall Street consensus targets $412.35 (27 analysts), implying a +42.2% move over the next 12 months. The stock is currently 25% below its 52-week high of $385.22, remaining 8.4% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.51B↑ | $1.50B↑ | $1.41B↑ | $1.32B↑ | $1.12B |
| Gross Profit | $1.35B↓ | $1.36B↑ | $1.22B↑ | $1.15B↑ | $952.28M |
| Operating Income | $249.90M↑ | $185.03M↑ | $163.11M↑ | $87.89M↑ | $11.10M |
| Net Income | $227.36M↑ | $66.50M↓ | $124.84M↑ | $94.32M↑ | $1.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
65.61
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.78%
Volume
Today's trading volume
313,823
Recent News
Here is Why BeOne (ONC) One of the Most Promising Long-Term Stocks to Buy According to Analysts
BeOne Medicines (NASDAQ:ONC) is one of the most promising long-term stocks to buy according to analysts. On June 1, BeOne presented new clinical data at the 2026 ASCO Annual Meeting, highlighting accelerated progress across three high-priority solid tumor development programs. The data validates the company’s strategy of pairing specific biological targets with advanced modalities, supporting […]
BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline
BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made the call after BeOne presented robust tumor clinical data at the American Society of Clinical Oncology (ASCO) […]
BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA
BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approved BTK inhibitor, BRUKINSA. The company markets BRUKINSA as a targeted prescription medication for the treatment of various types of […]
BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?
BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BeOne Medicines (ONC) Valuation Check After ASCO 2026 Solid Tumor Updates
BeOne Medicines (ONC) is back in focus after ASCO 2026 updates on three solid tumor drugs: its CDK4 inhibitor in breast cancer, a B7-H4 antibody drug conjugate in ovarian cancer, and a GPC3x4-1BB bispecific in liver cancer. See our latest analysis for BeOne Medicines. Despite the clinical buzz around ASCO, BeOne Medicines’ recent 30 day share price return is down 5.9% and the year to date share price return is down 10%. However, the 1 year total shareholder return is 8.92% and the 3 year...